Find Reports
Select Report Type
Reimbursement Review
Displaying 1276 - 1300 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| ataluren | Translarna | ataluren | Cancelled | SR0607-000 | |||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| vilazodone | Viibryd | vilazodone | Depression, Major depressive disorder | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0006-000 | |||
| ibrutinib | Imbruvica | ibrutinib | Chronic graft versus host disease | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0009-000 | |||
| eltrombopag | Revolade | eltrombopag | Severe aplastic anemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0007-000 | |||
| tezacaftor/ivacaftor | Symdeko | tezacaftor/ivacaftor | Cystic fibrosis, F508del mutation(s) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0008-000 | |||
| Abiraterone (Zytiga) for Prost... | Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | PC0201-000 | ||||
| Entrectinib (TBD) for Neurotro... | TBD | Entrectinib | Withdrawn | PC0157-000 | |||||
| ibrutinib | Imbruvica | ibrutinib | Leukemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0005-000 | |||
| pegaspargase | Oncaspar | pegaspargase | Adult Acute Lymphocytic Leukemia (ALL) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0002-000 | |||
| ibritumomab tiuxetan | Zevalin | iIbritumomab tiuxetan | Non-Hodgkin’s Lymphoma (NHL) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0003-000 | |||
| Atezolizumab (Tecentriq) for A... | Tecentriq | Atezolizumab | Withdrawn | PC0171-000 | |||||
| etonogestrel | TBC | etonogestrel | Prevention of pregnancy | Withdrawn | SR0629-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| filgrastim | TBC | filgrastim | Prevention or treatment of neutropenia in various indications | Cancelled | SE0585-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| pegfilgrastim | Fulphila | pegfilgrastim | Febrile neutropenia in non-myeloid malignancies | N/A | Complete | SE0588-000 | |||
| insulin glargine | Semglee | insulin glargine | Diabetes mellitus, Type 1 & 2 | Withdrawn | SE0589-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| Ogivri for Early Breast Cancer... | Ogivri | Trastuzumab | Withdrawn | PC0169-000 | |||||
| Zytiga for Prostate Cancer – D... | Zytiga | Abiraterone | Withdrawn | PC0166-000 | |||||
| fluocinolone acetonide | Iluvien | fluocinolone acetonide | Diabetic macular edema (DME) | Withdrawn | SR0549-000 | ||||
| CADTH Pharmaceutical Reviews U... | |||||||||
| filgrastim | TBC | filgrastim | Cancelled | SE0596-000 | |||||
| halobetasol propionate and taz... | TBC | halobetasol propionate and tazarotene | Psoriasis, moderate to severe plaque | Withdrawn | SR0600-000 |
Health Technology Review
Displaying 601 - 602 of 602
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 1276 - 1300 of 2138
Please scroll or swipe to the right to view the full content.
Provisional Funding Algorithm
Displaying 76 - 81 of 81